Treatment results of stereotactic interstitial brachytherapy for primary and metastatic brain tumors.
A total of 41 stereotactic interstitial brain implants in 39 patients were performed for recurrence after teletherapy (recurrence implant), or as part of initial treatment in conjunction with teletherapy (primary implant). Implanted tumors consisted of malignant gliomas (33), other primary brain tumors (3), and single metastatic lesions (3). All patients were temporarily implanted with Ir-192 using a coaxial catheter afterloading system; two patients were implanted twice. Survival post-implant for glioblastoma multiforme (GBM), 13 patients, was 10 months whether implanted primarily or for recurrence. Mean time to recurrence, measured from initiation of teletherapy to implantation, was 10 months. Twenty patients with anaplastic astrocytoma (AA) had a median survival post-implant of 23 months for primary implants (7 patients) and 11 months for recurrence implants (13 patients). Mean time to recurrence, measured from initiation of teletherapy to implantation, was 19 months. Three patients (9%) of the evaluable group required reoperation for symptomatic mass effect, all with initial diagnosis of AA. Survival for this subgroup was 14, 22, and 32 months post-implantation. Using stereotactic techniques, interstitial brachytherapy of brain tumors was technically feasible with negligible acute morbidity and mortality, and appeared to offer limited prolongation of control for a subset of patients with recurrent malignant gliomas. The role of this modality in primary treatment for malignant gliomas needs to be further defined by prospectively randomized trials.
Lucas
G L
GL
Dept. of Radiation Oncology, USC School of Medicine, Los Angeles 90033.
Luxton
G
G
Cohen
D
D
Petrovich
Z
Z
Langholz
B
B
Apuzzo
M L
ML
Sapozink
M D
MD
D000293:Adolescent; D000328:Adult; D000368:Aged; D001254:Astrocytoma / Q000453:epidemiology / Q000532:radiotherapy* / Q000556:secondary; D001918:Brachytherapy; D001932:Brain Neoplasms / Q000453:epidemiology / Q000532:radiotherapy* / Q000556:secondary; D005909:Glioblastoma / Q000453:epidemiology / Q000532:radiotherapy* / Q000556:secondary; D006801:Humans; D007496:Iridium Radioisotopes / Q000627:therapeutic use; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology / Q000532:radiotherapy; D012189:Retrospective Studies; D016019:Survival Analysis
D007496:Iridium Radioisotopes